title: Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization.
abstract: OBJECTIVE
  To report new indocyanine green angiographic (ICGA) findings after intravitreal bevacizumab (IVB) for myopic choroidal neovascularization (mCNV).
  
  
  METHODS
  Three eyes of three patients with mCNV were examined with fluorescein angiography (FA) and ICGA using Heidelberg Retinal Angiograph 2 and the conventional fundus camera before and after IVB. The cessation of angiographic leakage on FA was achieved in all eyes (100%) after IVB, however the hypofluorescent line delineating the margin of the neovascular tissue appeared in ICGA seemingly according to the contraction of mCNV. It was not detected either on FA or ICGA with the conventional camera. This hypofluorescence line enlarged over the time.
  
  
  CONCLUSIONS
  The contraction-associated hypofluorescence line, namely marginal crack line, indicates the early damage of retinal pigment epithelium and seems to lead to expanding macular chorioretinal atrophy typically seen in mCNV.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
authors.forename: Kaori
authors.initials: K
authors.lastname: Sayanagi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ikuno
authors.forename: Kaori
authors.initials: K
authors.lastname: Soga
authors.forename: Taku
authors.initials: T
authors.lastname: Wakabayashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D055213:Retinal Pigment Epithelium / Q000187:drug effects* / Q000473:pathology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab